Comparative Studies on Functionalization of Bacterial Magnetic Nanoparticles for Drug Delivery
- 24 Downloads
The study demonstrates the use of bacterial magnetic nanoparticles (BMNPs) as a drug carrier for the anticancer drug. BMNPs extracted from Magnetospirillum gryphiswaldense MSR-1, characterized using microscopic and spectroscopic methods. Drug conjugates were developed by direct binding of crizotinib with lipid membrane of BMNPs (CM) and also by using crosslinkers such as glutaraldehyde (CMG) and 3-aminopropyltriethoxysilane (APTES) (CMA). The developed conjugates were characterized using microscopic and spectroscopic methods. Drug loading capacity was 670 µg/ml for CM and 162.08 µg/ml and 243.15 µg/ml for CMG and CMA respectively. The drug loading efficiency of drug conjugates CM, CMG and CMA were found to be 67%, 16.2% and 24.3%. The drug release assay revealed slow and stable discharge of crizotinib from CM conjugate (8.2%) compared to CMG (88.33%) and CMA (58.46%) at 48 h. The cytotoxicity of CM was found to be high in comparison with BMNPs, CMG, CMA and crizotinib as tested on cell lines: A549, MCF-7 and HeLa. Our study establishes that the direct attachment of crizotinib with BMNPs shows better coupling with higher loading efficiency and long-term release compared to use of linkers. Further studies are needed to validate the results using animal models and also for targeted drug delivery.
KeywordsBMNPs Crizotinib BMNPs-drug conjugates Drug delivery Glutaraldehyde APTES
Bacterial magnetic nanoparticles
Deutsche Sammlung von Mikroorganismen und Zellkulturen
Magnetospirillum growth medium
Fourier-transform infrared spectroscopy
High-resolution transmission electron microscopy
Atomic force microscopy
Crizotinib-magnetosome complex prepared via glutaraldehyde
Crizotinib-magnetosome complex prepared via APTES
This work was supported by VIT University. The authors thank the management for providing the facilities for the research.
Compliance with Ethical Standards
Conflict of interest
There is no conflict of interest.
- 35.L. Krishnasamy, et al. (2014). Int. J. Pharm. Pharm. Sci.6, 245–248.Google Scholar